Brief: Equillium Announces Up To $50 Million Financing To Advance EQ504, A Novel Aryl Hydrocarbon Receptor Modulator, Into The Clinic
11/08/2025 13:57
Aug 11 (Reuters) - Equillium Inc EQ.O: EQUILLIUM ANNOUNCES UP TO $50 MILLION FINANCING TO ADVANCE EQ504, A NOVEL ARYL HYDROCARBON RECEPTOR MODULATOR, INTO THE CLINIC EQUILLIUM INC - PHASE 1 STUDY INITIATION PLANNED MID-2026, DATA EXPECTED 6 MONTHS LATER EQUILLIUM INC - EXPECTS CASH RUNWAY EXTENSION THROUGH 2027 Source text: ID:nBwbfp0M4a Further company coverage: EQ.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Equillium
See all newsBrief: Equillium Receives Australian Regulatory Clearance To Initiate First-In-Human Clinical Trial Of Eq504
Equillium Inc reports results for the quarter ended June 30 - Earnings Summary
Equillium Q2 post narrower net loss than expected; starts R&D initiatives
Equillium Inc expected to post a loss of 5 cents a share - Earnings Preview
Equillium Q1 net loss, profit miss analyst expectations